The core strategy of the NEOMERO Project includes the combination of two clinical trials: Neomero1 (an open-label, randomised, multicenter, comparator-controlled study to evaluate the PK, efficacy and safety of meropenem as compared with standard antibiotic therapy in neonates and infants aged < 3 months treated in neonatal intensive care units (NICU) for late onset sepsis (LOS) defined as sepsis appearing after 72 hrs from birth) and NeoMero2 (an open label, multicenter, observational study to evaluate the PK and safety of meropenem in neonates and infants aged < 3 months with bacterial meningitis admitted to NICUs).

As of December 27th, 2013, the trial status is the following: 166 patients have been randomised in NM1 study and 25 patients have been included in NM2 study.

About the Author: admin


By Published On: December 27th, 2014Categories: News0 CommentsTags: , ,